145 related articles for article (PubMed ID: 32429447)
1. The Over-Expression of E2F3 Might Serve as Prognostic Marker for Neuroblastoma Patients with Stage 4S Disease.
Parodi S; Ognibene M; Haupt R; Pezzolo A
Diagnostics (Basel); 2020 May; 10(5):. PubMed ID: 32429447
[TBL] [Abstract][Full Text] [Related]
2. E2F3 gene expression is a potential negative prognostic marker for localised and MYCN not-amplified neuroblastoma: Results of in silico analysis of 786 samples.
Ognibene M; Cangelosi D; Sorrentino S; Zanardi S; Zara F; Pezzolo A; Parodi S
Pediatr Blood Cancer; 2022 Oct; 69(10):e29800. PubMed ID: 35652628
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of E2F transcription factors E2F1 and E2F3 in four independent pediatric neuroblastoma cohorts.
Wang H; Wang X; Xu L; Zhang J
BMC Pediatr; 2022 Jun; 22(1):376. PubMed ID: 35764946
[TBL] [Abstract][Full Text] [Related]
4. Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.
Decock A; Ongenaert M; De Wilde B; Brichard B; Noguera R; Speleman F; Vandesompele J
Epigenetics; 2016 Oct; 11(10):761-771. PubMed ID: 27599161
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factor analysis of stage 4S neuroblastoma in infant patients: A single center study.
Wang Z; Sun H; Li K; Yao W; Dong K; Ma Y; Zheng S
J Pediatr Surg; 2019 Dec; 54(12):2585-2588. PubMed ID: 31521373
[TBL] [Abstract][Full Text] [Related]
6. Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry.
Parodi S; Sorrentino S; Cataldo AD; Tondo A; Fagnani AM; Perri P; Gigliotti AR; Erminio G; Corrias MV; De Bernardi B
Pediatr Blood Cancer; 2021 May; 68(5):e28904. PubMed ID: 33459514
[TBL] [Abstract][Full Text] [Related]
7. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
[TBL] [Abstract][Full Text] [Related]
9. Rb-independent E2F3 promotes cell proliferation and alters expression of genes involved in metabolism and inflammation.
Liao Y; Du W
FEBS Open Bio; 2017 Oct; 7(10):1611-1621. PubMed ID: 28979847
[TBL] [Abstract][Full Text] [Related]
10. Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
Iehara T; Hiyama E; Tajiri T; Yoneda A; Hamazaki M; Fukuzawa M; Hosoi H; Sugimoto T; Sawada T
Eur J Cancer; 2012 Jul; 48(11):1707-12. PubMed ID: 22305511
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of telomerase activity in patients with neuroblastoma.
Nozaki C; Horibe K; Iwata H; Ishiguro Y; Hamaguchi M; Takahashi M
Int J Oncol; 2000 Aug; 17(2):341-5. PubMed ID: 10891545
[TBL] [Abstract][Full Text] [Related]
12. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
[TBL] [Abstract][Full Text] [Related]
13. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.
Tas ML; Nagtegaal M; Kraal KCJM; Tytgat GAM; Abeling NGGM; Koster J; Pluijm SMF; Zwaan CM; de Keizer B; Molenaar JJ; van Noesel MM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28061. PubMed ID: 31736229
[TBL] [Abstract][Full Text] [Related]
15. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
[TBL] [Abstract][Full Text] [Related]
16. [miR-503-5p inhibits the proliferation of T24 and EJ bladder cancer cells by interfering with the Rb/E2F signaling pathway].
Li X; Han X; Yang J; Sun J; Wei P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Oct; 33(10):1360-1364. PubMed ID: 29169421
[TBL] [Abstract][Full Text] [Related]
17. Stage 4S neuroblastoma, a disseminated tumor with excellent outcome.
Elimam NA; Atra AA; Fayea NY; Al-Asaad TG; Khattab TM; Al-Sulami GA; Felimban SK
Saudi Med J; 2006 Nov; 27(11):1734-6. PubMed ID: 17106552
[TBL] [Abstract][Full Text] [Related]
18. Successful living-donor liver transplantation for sustained liver failure even after resolution of infiltrative massive hepatic invasion of stage 4S neuroblastoma: a case report.
Jobara K; Yamamori A; Shizuku M; Kurata N; Fujimoto Y; Muramatsu H; Takahashi Y; Ogura Y
Surg Case Rep; 2023 Jun; 9(1):100. PubMed ID: 37286818
[TBL] [Abstract][Full Text] [Related]
19. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
Aslanian A; Iaquinta PJ; Verona R; Lees JA
Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
[TBL] [Abstract][Full Text] [Related]
20. Proteomics-based identification of spontaneous regression-associated proteins in neuroblastoma.
Yu F; Zhu X; Feng C; Wang T; Hong Q; Liu Z; Tang S
J Pediatr Surg; 2011 Oct; 46(10):1948-55. PubMed ID: 22008333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
